Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation
BeiGene, Hengrui Head Local R&D Push
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
You may also be interested in...
Sweeping regulatory reforms put China in catch-up mode for the approval of oncology drugs, some of which have been cleared for marketing only in the country. But how does the deluge of new products measure up in terms of actual overall survival benefits? A new study by Peking University scholars and specialists unveils some surprising results.
The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.
The latest approval for AnNiKe (penpulimab) from Akeso/Sino Biopharm adds further competition to a crowded space where six PD-1 immuno-oncology drugs elbow each other.